Evelo Biosciences (EVLO) Short Interest Ratio & Short Volume

Short interest is the volume of Evelo Biosciences shares that have been sold short but have not yet been closed out or covered. As of August 31st, investors have sold 6,800 shares of EVLO short. 0.04% of Evelo Biosciences' shares are currently sold short. Learn More on Evelo Biosciences' current short interest.

The short interest ratio, also known as the "days to cover ratio", is calculated by dividing the number of shares of a stock sold short divided by its average trading volume. A short interest ratio ranging between 1 and 4 generally indicates strong positive sentiment about a stock and a lack of short sellers. A short interest ratio of 10 or greater indicates strong pessimism about a stock. EVLO shares currently have a short interest ratio of 10.0. Learn More on Evelo Biosciences's short interest ratio.

Companies that have a short interest as a percentage of float below 10% indicates positive investor sentiment and few short sellers. Stocks with a short interest percentage above 10% is considered high, suggesting some investors are pessimistic about the stock. Companies with a short interest percentage of 20% or more indicates widespread negative sentiment. 0.04% of Evelo Biosciences' floating shares are currently sold short.

Evelo Biosciences saw a increase in short interest in August. As of August 31st, there was short interest totaling 6,800 shares, an increase of 1.5% from the previous total of 6,700 shares. Changes in short volume can be used to identify positive and negative investor sentiment. Investors that short sell a stock are betting that its price will decline in the future. An increase in short sale volume suggests bearish (negative) sentiment among investors. A decrease on short sale volume suggests bullish (positive) sentiment.

0.04% of Evelo Biosciences' shares are currently sold short. Here is how the short interest of companies in the industry of "pharmaceutical products" compare to Evelo Biosciences: Scopus BioPharma Inc. (0.03%), Smart for Life, Inc. (0.01%), Virpax Pharmaceuticals, Inc. (0.25%), Statera Biopharma, Inc. (0.15%), Comera Life Sciences Holdings, Inc. (0.02%), Genocea Biosciences, Inc. (0.33%), Aridis Pharmaceuticals, Inc. (0.05%), Ampio Pharmaceuticals, Inc. (0.01%), PaxMedica, Inc. (0.01%), Calithera Biosciences, Inc. (0.15%),

As of the most recent reporting period, the following stocks had the largest short interest positions: SPDR S&P 500 ETF Trust ($73.23 billion), Invesco QQQ ($29.52 billion), iShares Russell 2000 ETF ($20.82 billion), iShares 20+ Year Treasury Bond ETF ($10.76 billion), Palo Alto Networks, Inc. ($9.37 billion), Strategy Inc ($7.58 billion), Invesco S&P 500 Equal Weight ETF ($6.78 billion), SPDR S&P Biotech ETF ($6.72 billion), AppLovin Corporation ($6.37 billion), and iShares iBoxx $ Investment Grade Corporate Bond ETF ($6.29 billion). View all of the most shorted stocks.

Short selling EVLO is an investing strategy that aims to generate trading profit from Evelo Biosciences as its price is falling. To short a stock, an investor borrows shares, sells them and buys the shares back on the public market later to return it to the lender. Short sellers are betting that a stock will decline in price. If the stock does drop after selling, the short seller buys it back at a lower price and returns it to the lender. The difference between the sell price and the buy price is the trader's profit.

A short squeeze for Evelo Biosciences occurs when it has a large amount of short interest and its stock increases in price. This forces short sellers to cover their short interest positions by buying actual shares of EVLO, which in turn drives the price of the stock up even further.

Short interest is typically published by a stock exchange once per month. However, NASDAQ publishes a report for U.S. stocks, including EVLO, twice per month. The most recent reporting period available is August, 31 2025.